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Abstract
Atherosclerosis is increasingly recognized as a complex chronic inflammatory disease. Many
more studies have extended vaccination against atherosclerosis by using epitopes from self-
antigens or beyond and demonstrated that vaccination with antigens or derivatives could re-
duce the extent of the lesions in atherosclerosis-prone mice. Our previous study has demon-
strated that construct AHHC [ApoB100688-707 + hHSP60303-312 + hHSP60153-163 + Cpn
derived peptide (C)] significantly reduced atherosclerotic lesion. The aim of this study was to
investigate whether AHHC can be modulated towards increased lesion reduction in mice by
creating two other derivatives with a sequential epitope-substitution named RHHC in which A
was replaced by an “R” (C5aR1-31) and RPHCwith a further “H” (hHSP60303-312) conversion
into “P” (protease-activated receptor-142-55) in mice. Antigenic epitopes were incorporated
into a dendroaspin scaffold. Immunization of B6;129S-Ldlrtm1HerApobtm2Sgy/J mice with three
constructs elicited production of high levels of antibodies against each epitope (apart from
hHSP60153-163 and P which induced a low antibody response). Histological analyses demon-
strated that the mice immunized with either RPHC or RHHC showed significant reductions
in the size of atherosclerostic lesions compared to those with AHHC (69.5±1.1% versus
55.7±3.4%, P<0.01 or 65.6±1.3% versus 55.7±3.4%, P<0.01). Reduction of plaque size in
the aortic sinus and descending aorta correlated with alterations in cellular immune re-
sponses when compared with controls. We conclude that a recombinant construct RPHC
may provide new antigenic and structural features which are favorable for significant reduc-
tion in atherosclerotic lesion formation. This approach offers a novel strategy for developing
anti-atherosclerotic agents.
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Introduction
Atherosclerosis is increasingly recognized as a complex chronic inflammatory disease of the ar-
terial walls [1–3] as evidenced by the presence of inflammatory cells, activated immune cells
and cytokines in lesions, all of which indicate involvement of the immune system [4,5]. Den-
dritic cells (DCs) are likely to play a crucial role in directing innate and adaptive immunity. A
major component of the innate response involves the entry of monocytes into nascent lesions,
followed by differentiation of monocytes into macrophages and CD11c+ cells with DC-like
properties [6]. Atherosclerotic plaques are known to contain macrophage-derived foam cells in
which macrophages interact with T cells to produce a wide array of cytokines that can
exert both
pro- and anti-inflammatory effects [7,8]. Although the molecular mechanism responsible
for the development of atherosclerosis is not completely understood, it is clear that the immune
system plays a key role in the development of the atherosclerotic plaque and in its complica-
tions. Consequently, several antigenic stimuli that are associated with the pathogenesis of ath-
erosclerosis based on modified self-molecules or peptides derived from these molecules such as
oxidized low-density lipoproteins (oxLDLs) [9,10], β2-glycoprotein I (β2GP1), phosphatidyl-
choline (PC) [11,12], heat shock proteins (HSPs), [13] have been reported. Many more studies
related to vaccination against atherosclerosis apart from using epitopes from these self-antigens
have also demonstrated high efficacy against atherosclerotic lesion formation for other antigens
[14,15]. However, one of the difficulties in developing effective vaccination strategies against
atherosclerosis is the selection of a specific antigen. In the discovery and development of poten-
tial antigens, we have previously demonstrated that immunization of B6;129S-Ldlrtm1HerA-
pobtm2Sgy/Jmice with the recombinant construct AHHC containing epitopes derived from
apolipoprotein B (ApoB), heat shock protein (HSP) 60 and proteins of Chlamydia pneumoniae
(Cpn), significantly reduced atherosclerotic lesion formation in the mice fed with high-fat diet
(HFD) [16]. In addition, we have also demonstrated that immunization with peptides derived
from the N-terminal of complement component 5a receptor (C5aR) significantly reduced early
atherosclerotic lesion development in B6;129S-Ldlrtm1HerApobtm2Sgy/Jmice [17]. Furthermore,
in preclinical studies, protease-activated receptor (PAR)-1 inhibition showed a strong antith-
rombotic effect, leading to a significant decrease in platelet aggregation, whereas primary hae-
mostatic function was preserved [18] and our recent study in B6;129S-Ldlrtm1HerApobtm2Sgy/J
mouse model showed that PAR-1 peptide significantly attenuated atherosclerotic lesion forma-
tion[19]. Based on the effects of the peptides derived from C5aR and PAR-1 on reducing the
atherosclerotic lesion, we hypothesized that the effect of a multi-epitopic construct on reducing
atherosclerotic lesion may be modulated towards favorable plaque phenotype and increased le-
sion reduction with inclusion of C5aR and PAR-1 in vaccination. In the present study we inves-
tigated the effect of C5aR and PAR-1 including constructs through a sequential substitution:
AHHC!RHHC (R denotes an epitope derived from C5aR) in RHHC!RPHC (P denotes an
epitope derived from PAR-1) on reducing atherosclerotic lesion.
Methods
1. Expression and purification of recombinant glutathione S-transferase
constructs
Glutathione S-transferase-dendroaspin (GST-Den here referred to as a control, S1A Fig) and
GST-recombinant construct AHHC [ApoB100 peptide, amino acids (aa) 688–707 (numbered
including signal peptide), human heat shock protein (hHSP) 60 peptide, aa 303–312 and
aa153-163, respectively; and Chlamydia pneumoniae (Cpn) derived epitope (“C”, denotes a
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combination of aa 66–73 from major out membrane protein (MOMP) and aa 283–291 from
outer membrane 5 of Cpn)] was described previously and construct RHHC (“R” denotes a
C5aR peptide, aa 1–31) and RPHC (“P” denotes an protease activated receptor-1 (PAR-1) pep-
tide, aa 42–55) were generated. Schematic presentation of these constructs using dendroaspin
as a scaffold is shown in S1B Fig These recombinant molecules were expressed in Escherichia
coli (BL-21 strain), purified by affinity and ion exchange chromatography and analyzed by so-
dium dodecyl sulfate polyacrylamide gel electrophoresis, all these procedures were similar to
those described for AHHC previously [16].
2. Animal experiments
The experiments were approved by the Animal Welfare Committee of the University of Szeged
and conform to the Directive 2010/63/EU of the European Parliament.
Low-density lipoprotein receptor–deficient apolipoprotein B-100-only mice were used in
our study, each group of mice consisting of 5-6-week-old males. We used dendroaspin as a
control antigen, since dendroaspin was used as a scaffold and our previous data showed no ef-
fect of dendroaspin on lesion reduction when used for subcutaneous immunization in mice
[16].
The immunizing antigens used were constructs AHHC, RHHC and RPHC, respectively.
The repetitive immunization multiple sites strategy (RIMMS) was adopted [1] and mice were
sacrificed at the end of week 12 (a high-fat diet was started at the end of week 2 and continued
for 10 weeks). The control groups followed the diet program after immunization with GST-
tagged Den and Alum (adjuvant).
3. Tissue preparation and antibody response measurements
Twelve weeks after the first immunization, aorta tissues were harvested and mounted in
optimal cutting temperature compound (OCT) and in paraffin, for immunohistochemical
(IHC) analyses and lesion measurement, respectively. Atherosclerotic lesions in aortic roots
were examined by an Olympus UULH Optical microscope (Olympus Optical Co. Ltd, Tokyo,
Japan) and analyzed with Image-Pro Plus software, version 7.0 (Media Cybernetics, Inc., Be-
thesda, MD, USA). Longitudinally opened descending aortas were evaluated for the extent of
atherosclerosis after Oil Red O (ORO) staining. The peptide-specific antibody levels in the
plasma samples were measured by ELISA following the manufacturer’s instructions. One third
of spleens were embedded in OCT and the remaining part was homogenized by pressing
through 70 μm cell strainer and frozen for further analysis.
4. IHC and morphometric analyses, quantitative measurements of
atherosclerosis, and IHC analysis of forkhead box protein 3 (Foxp3)
expression in CD4+ splenocytes
OCT-embedded samples were used for detection of CD68, CD11c, Interleukin (IL)-10 and
tumor necrosis factor (TNF)-α, Foxp3, vascular cell adhesion molecule (VCAM)1, alpha
smooth muscle cell (alpha-SMC), matrix metalloproteinase 9 (MMP9) by IHC analyses. Sec-
tions of paraffin-embedded tissues were stained with hematoxylin and eosin (HE) and elastin/
van Gieson (Sigma) for histological examination by the Olympus U-ULH Optical microscope.
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5. Flow cytometric analysis of Foxp3, IL-2, IL-4 and IL-17A expression in
CD4+ T-cells in splenocytes and differentiation of PBMC into macrophage
(CD206)
Spleen cells were processed for staining (30 min at 4°C) using allophycocyanin-anti-mouse
Foxp3, IL-2, IL4 and IL-17 antibodies (BioLegend, Cambridge, UK). For cell differentiation
assay, mouse (C57BL/6) PBMCs were stimulated with different antigens or pre- incubated
with antiserum of antigen (in order to see any antagonism of antiserum). Antigen-induced dif-
ferentiation of monocytes into macrophages was measured by flow cytometry which was com-
pared to cell populations from non-induced cells or control antigen (GST-Den)-induced cells.
6. Measurement of cytokines
IL-10 and TNF-α levels in the lesions were quantified by IHC analyses (rat anti-mouse TNF-α
and IL-10 purchased from BioLegend, CA, USA). Plasma levels of the cytokines, IL-10, trans-
forming growth factor beta (TGF-β), TNF-α and interferon gamma (IFN-γ) were measured by
ELISA following the manufacturer’s instructions (R&D systems, Abingdon, UK). Levels of con-
canavalin A (ConA)-induced IL-10, TGF-β, TNF-α, and IFN-γ in splenocyte cultures were
also measured.
7. Antigen-specific regulatory T cell function assays
To assess antigen-specific regulatory T cell function, CD4+CD25+ Treg cells were isolated by
using regulatory T cell isolation kit of Miltenyi Biotec (Bergisch Gladbach, Germany) from
spleen CD4+ T cells of B6;129S-Ldlrtm1HerApobtm2Sgy/Jmice immunized subcutaneously with
constructs, respectively. CD4+CD25− T effector cells were isolated from spleen CD4+ T cells
(unbound to beads binding CD4+CD25+ cells, 99.5% of CD4+ cells) of same construct-immu-
nized mice respectively. CD4+CD25− cells (2×105) were co-cultured with CD4+CD25+ cells
(2×105), and stimulated with 1 μM related construct or with GST-Den control. After 2 days of
culture, the proliferation of T effector cells was measured for the shift in fluorescence intensity
of a population of cells by flow cytometry expressed as mean fluorescence intensity (MFI).
8. Statistical analyses
Data are reported as mean±standard error of the mean (±SEM), unless otherwise indicated.
Figures were plotted using graph-pad Prism 5.01 and Sigma plot 9.0. For atherosclerotic lesion
size, data were compared and intergroup differences were analyzed using one-way ANOVA for
multiple comparisons and post hoc Bonferroni test. Other data were analyzed using Student’s
t-test (2-tailed analyses). Non-parametric distributions were analyzed using the Mann-Whit-
ney U test for pair wise comparisons and the Kruskal-Wallis test for multiple comparisons. Dif-
ferences between groups were considered significant at P values below 0.05. An extended
description is available as S1 Text, S1 Table, S1 Fig, S2 Fig, S3 Fig, S4 Fig, and S5 Fig.
Results
1. Peptide-specific immunoglobulin G in the sera of immunized mice
Antibody levels were measured by ELISA test in the sera of mice immunized with either den-
droaspin (GST-tagged) or constructs within dendroaspin scaffold (GST-tagged) at weeks 2 and
week 12 respectively after first immunization. In AHHC-immunized mice, ApoB peptide-,
hHSP60303-312- and Cpn-peptide-specific antibodies were observed when these peptides were
used as ELISA antigens (Fig 1A). Similarly C5aR peptide-specific antibodies were detected in
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addition to observed hHSP60303-312- and Cpn peptide- specific antibodies in mice immunized
with RHHC (Fig 1A). High antibody levels against Cpn peptide and C5aR peptide whereas low
antibody level against PAR-1 peptide was detected in mice immunized with RPHC (Fig 1A).
Low antibody level against hHSP60153-163 was observed in mice immunized with any construct
(Fig 1A). Overall observed optical density (OD) values at 100 dilutions were reduced at week
12 compared to those at week 2.
Interestingly, a peptide-induced specific immunoglobulin (Ig)G1 response was observed in
serum of peptide-immunized mice against all peptide antigen epitopes at high dilutions except
for those against hHSP60153-163 and PAR-1 peptides when compared with GST-Den control
(Fig 1B). In addition, a similar pattern for IgG2c response was also detected but with low
serum dilutions when compared with that in control (Fig 1C). However, the levels of IgG2c de-
tected were much lower than those of IgG1 based on the optical densities measured in different
dilutions of samples (1:50 versus 1:6250). Furthermore, using antiserum at week 8, certain lev-
els of cross-reactions were observed between ApoB peptide-induced antiserum and Cpn pep-
tide (Fig 1D), between ApoB peptide- and hHSP60303-312 peptide- induced antiserum and their
antigens (Fig 1E), between ApoB peptide-induced antiserum and antigens of either PAR-1 pep-
tide or C5aR peptide (Fig 1F) and between C5aR peptide-induced antiserum and antigens of ei-
ther ApoB peptide or PAR-1 peptide (Fig 1G). Apart from cross-reaction between Cpn peptide
and ApoB peptide antiserum when pooled sera were tested and thus no SD values were calcu-
lated (Fig 1D), the other cross-reactions showed significant difference compared to the controls
(Fig 1E–1G; P<0.05~<0.001).
Fig 1. Levels of constructed protein-induced IgG, IgG1, and IgG2c antibodies in the sera of B6;129S-Ldlrtm1HerApobtm2Sgy/Jmice at 2 weeks and 12
weeks respectively, after the first immunization and in controls (GST-Den-immunized mice). The mean optical densities (ODs) and SEM obtained from
plasma samples of constructs AHHC, RHHC, and RPHC-immunized mice on Cpn peptide
(C)-, hHSP60153-163 (H)-, hHSP60303-312 (H)-, C5aR-peptide (R)-, ApoB peptide (A)-, PAR-1(P)-coated ELISA plates are shown. (A) IgG at the dilution ratio:
1:100. (B) IgG1 at the dilution ratio: 1:6250. (C) IgG2c at the dilution ratio: 1:50. (D) Cross reaction between human ApoB peptide-induced antiserum and Cpn
peptide. (E) Cross reaction between human ApoB peptide- and hHSP60303-312 peptide-induced antiserum and their antigens. (F) Cross reaction between
ApoB peptide-induced antiserum and antigens of either PAR-1 peptide or C5aR peptide. (G) Cross reaction between C5aR peptide-induced antiserum and
antigens of either ApoB peptide or PAR-1 peptide. Antiserum used for cross-reaction was taken at week 8.
doi:10.1371/journal.pone.0123393.g001
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2. Reduction of atherosclerotic lesion size in the aortic sinus
Following immunization with AHHC, RHHC, RPHC, and after a 10-week high-fat diet, the
aortic sinuses of the mice were evaluated for the extent of atherosclerosis. The calculated plaque
sizes from the immunized animals were compared with those of the controls. Representative
photomicrograph of sections with lesions from experimental groups are shown in Fig 2A. The
plaque areas are shown in Fig 2B. Lesion size was smaller in mice immunized with all three
constructs showing 31,071 ± 998.7 μm2, 24,123 ± 1967μm2 and 21,386 ± 2482 μm2 (P<0.001)
compared with controls (70,200 ± 5718 μm2). The smaller lesion area was observed in mice im-
munized with either RHHC or RPHC compared with mice immunized with AHHC
(P = 0.007–0.002) (Fig 2B). The percentage of reduction in lesion size is shown in Fig 2C, show-
ing 55.7 ± 3.4%, 65.6 ± 1.3% and 69.5 ± 1.1% when assuming reduction in lesion of control ani-
mals as zero percent. The control mice that were immunized with GST-Den showed similar
Fig 2. Detection and quantitation of the lesion areas in the aorta of B6;129S-Ldlrtm1HerApobtm2Sgy/Jmice fed on a high-fat diet after immunization
with constructs versus controls (GST-Den). (A) Photomicrograph of lesions observed in atherosclerotic aortas as analyzed with elastin/van Gieson
staining. (B) Scatter plot showing mean of lesion area in the aortic sinus of mice immunized with constructs compared with those in controls (GST-Den).
(N = 6–9 mice). Error bars = SEM. (C) Percentage of reduction in lesion size in the aortic sinus (the reduction of control [GST-Den] group was set at zero). (D)
Representative photomicrographs and quantitative analysis of collagen (Sirius Red coloration under polarized light) in atherosclerotic aortas in individual
mice. (E) Quantification of collagen content at lesion area in the aorta of B6;129S-Ldlrtm1HerApobtm2Sgy/Jmice (N = 7 mice). NS: not significant. (F)
Representative Oil Red O-stained en face descending aorta frommice. (G) Percentage of lesion-occupied area versus total area of descending aortas in
individual mice (N = 6 mice) of the different experimental groups. The mean lesion size and the difference in lesion size between the experimental groups are
shown. (H) Percentage of reduction in lesion size in descending aortas (the reduction of control [GST-Den] group was set at zero).
doi:10.1371/journal.pone.0123393.g002
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lesion formation in either GST-tag-or Alum (adjuvant)-immunized controls (S2A and S2B
Fig). Therefore, we took GST-Den as a control throughout the experiment.
In addition, we examined the impact of treatment with these recombinant constructs on the
collagen content in these lesions. The reduction of atherosclerosis in mice treated with these
constructs was associated with an increase in collagen content: approximately 3-fold for either
AHHC-immunized mice or RHHC-immunized mice versus control mice (18.6 ± 1.2% or
19.4 ± 0.9% versus control 5.9 ± 0.3%; P<0.001), respectively (Fig 2D and 2E). Mice immu-
nized with in RPHC showed a significant collagen increase (24.4 ± 0.9%) compared with mice
immunized with either AHHC or RHHC (P = 0.003, and P = 0.007, respectively).
Longitudinally opened descending aortas were stained en face with oil red O (ORO) and
positively stained plaques areas were measured. Representative en face stained descending aor-
tas from experimental groups are shown in Fig 2F. Lesion size was significantly smaller in mice
immunized with any construct showing 8.4 ± 0.3%, 6.6 ± 0.3% and 6.4 ± 0.4% for AHHC,
RHHC, and RPHC, respectively compared with controls (19.5 ± 1.7%, P<0.001) (Fig 2G).
Both RHHC- and RPHC-immunized mice showed significantly less lesion than AHHC-immu-
nized mice (P = 0.011–0.008). The reduction of lesions expressed as a percentage is shown in
Fig 2H with 57.3 ± 1.7%, 66.1 ± 1.6% and 67.3 ± 1.9% for AHHC, RHHC, RPHC, respectively.
The smallest lesion area was observed in mice immunized with RPHC.
3. Amount of inflammatory cells and CD4+ T cells expressing Foxp3 in
local (lesions of aortas) and remote organs: splenocytes and
lymphocytes
The percentage of anti-CD68-stained area in the lesions showed 14.9 ± 1.6%, 13.6 ± 1.3% and
10.3 ± 0.8% in mice immunized with AHHC, RHHC and RPHC, respectively compared to
43.7 ± 3.2% in control mice immunized with GST-Den (P<0.001). Lesser anti-CD68-stained
area was observed in RPHC-immunized mice compared with that in AHHC-immunized mice
(P = 0.034) (Fig 3A and 3B). Similarly, measurement of anti-CD11c-stained lesion area showed
13.3 ± 2.1%, 10.5 ± 1.5% and 7.9 ± 0.8% in mice immunized with AHHC, RHHC and RPHC,
respectively compared to 38.4 ± 1.9% in control mice (P<0.001) (Fig 3A and 3C). Anti-
CD11c-stained lesion area in RPHC-immunized mice was significantly smaller when
compared with that in AHHC-immunized mice (P = 0.039) (Fig 3A and 3C). Double immu-
nostaining for CD68 and CD11c clearly revealed that more than half of macrophages were
CD68+CD11c+, indicating the myeloid origin of this cell type in lesions as CD11c+ area co-lo-
calized with CD68+ area expressed as percentage showing 54.7 ± 3.7%, 55.2 ± 2.6% and
50.3 ± 3.3% for AHHC, RHHC and RPHC, respectively compared to 68.6 ± 4.7% in control
mice (Fig 3A–3D; P = 0.046–0.011) [20].
The proportion of CD4+ cells expressing Foxp3 analyzed by IHC staining of aorta sections
was approximately 6- to 8-fold higher (8.2 ± 1.4%, P<0.001; 9.4 ± 1.1%, P<0.001; 9.9 ± 1.6%,
P<0.001) in mice immunized with AHHC, RHHC and RPHC, respectively compared to
1.2 ± 0.2% in control mice (P<0.001) (Fig 3E and 3F). In addition, expression of Foxp3 in
CD4+ spleen cells from mice immunized with these three constructs was higher (P<0.001)
than that in controls, showing 13.3 ± 0.6%, 15.3 ± 1.5%, and 18.0 ± 1.1%, for AHHC, RHHC
and RPHC respectively versus 4.0 ± 0.5% in controls (Fig 3G and 3H). With the exception of
RPHC-immunized mice, which did not show a significant increase of Foxp3 expression when
compared with that in RHHC-immunized mice, however, significantly higher levels of Foxp3
expression were observed in comparison with that in AHHC-immunized mice (P = 0.002).
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4. Expression of anti-inflammatory cytokines and proinflammatory
cytokines in lesion sites and levels of cytokines in plasma and in the
supernatants of stimulated splenocytes
IL-10 expression in the aortic lesions of mice immunized with AHHC, RHHC and RPHC, de-
tected by IHC analyses is shown in Fig 4A. The proportion of CD4+ cells expressing IL-10 in
the lesions was approximately 6-fold higher in mice immunized with these constructs, showing
4.8 ± 0.7%, 5.2 ± 0.8% and 5.9 ± 0.7% (P<0.001) for AHHC, RHHC and RPHC, respectively
when compared with that in the control group (0.9 ± 0.2%) as shown in Fig 4A and 4B. IHC
analyses of TNF-α expression showed significantly smaller TNF-α-occupied areas in lesions of
mice immunized with constructs compared with controls (25.7 ± 3.1% for AHHC; 15.2 ± 0.9%
for RHHC; 15.5 ± 1.5% for RPHC and 41.3 ± 3.1% for controls) (Fig 4C and 4D). These data
represent a percent reduction of 37.8%, 63.2%, and 62.5%, respectively, compared with controls
(total lesion area defined as 100% and 0% reduction). Additionally, enhanced reduction was
produced by either RHHC or RPHC versus AHHC (P = 0.008–0.014).
Plasma levels of atheroprotective cytokines IL-10 were significantly increased in mice im-
munized with these three constructs compared with controls (Fig 4E and 4F). Immunization
with RPHC had more effect than with other two constructs on promoting the secretion of IL-
10 and TGF-β (P<0.05 to<0.001). Plasma levels of the atherogenic cytokine TNF-α were sig-
nificantly reduced by immunization with these three constructs (Fig 4G). A similar trend was
Fig 3. Assessment of inflammation-associated cells in the lesions of B6;129S-Ldlrtm1HerApobtm2Sgy/Jmicemice fed a high-fat diet after
immunization with constructs AHHC, RHHC, and RPHC. (A) Photomicrographs showing IHC staining of CD68 (green) and CD11c (red) markers (scale
bar: 100 μm and 12.5μm for magnified ones). (B) Scatter plot showing anti-CD68-stained area in lesion versus total lesion area; Data are given as the mean
of 6 mice. (C) Scatter plot showing anti-CD11c-stained area in lesion versus total lesion area; Data are given as the mean of 6 mice. (D) Co-localization of
CD68+ and CD11c+ areas (derived from Fig 3B and 3C). (E) Photomicrographs showing IHC staining of CD4+ T-cells (green) and Foxp3+ Treg cells (red)
(scale bar: 100 μm and 12.5μm for magnified ones). (F) Scatter plot showing anti-Foxp3-stained area versus anti-CD4+ stained area in lesion (N = 6). (G)
Representative analysis of Foxp3 expression by CD4+ T cells in lymph nodes from construct-immunized mice fed on a high-fat diet as assessed using flow
cytometry. (H) Percentage of Foxp3+ cells among CD4+ spleen cells as analyzed by flow cytometry. Data are expressed as mean of 3 analyses ± SEM.
Differences between groups are shown.
doi:10.1371/journal.pone.0123393.g003
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obtained for these constructs in respect of plasma levels of IFN-γ (Fig 4H). Notably, immuniza-
tion with RPHC had more effect than with AHHC on reducing the secretion of TNF-α and
IFN-γ (P0.002) and more effect than with RHHC on reducing the secretion of TNF-α
(P = 0.004). Although slightly higher plasma levels of IFN-γ from mice immunized with
AHHC was observed compared to that of control mice (24 versus 20.8 pg/ml), this difference
did not show statistical significance.
Fig 4. Assessment of IL-10-producing T cells, TNF-α expression in the lesions and cytokine levels in B6;129S-Ldlrtm1HerApobtm2Sgy/Jmice fed a
high-fat diet after immunization with constructs AHHC, RHHC, and RPHC. (A) Photomicrographs showing dual-IHC staining for IL-10 (red) and CD4
(green) (scale bar: 100 μm and 12.5μm for magnified ones). (B) Scatter plot showing mean of IL-10-positive area co-localized with CD4+ area (%) (N = 6). (C)
Photomicrographs showing IHC staining for TNF-α (green) of lesions (scale bar: 100 μm and 12.5μm for magnified ones). (D) Scatter plot showing mean of
anti- TNF-α-stained area in the lesion versus total lesion area (N = 6). (E-H) Cytokine levels measured in plasma. (I-L) Cytokine levels measured in the
supernatant of splenocytes stimulated with ConA. (M) Representative analysis of CD4+IL-4+ T-cells in splenocytes from construct-immunized mice fed on a
high-fat diet as assessed by flow cytometer. (N) Percentages of IL-4+ expressing CD4+ spleen cells. Data are expressed as mean of 3 analyses ± SEM.
Differences between groups are shown. (O) Representative analysis of IL-17A expression by CD4+ T-cells in splenocytes from construct-immunized mice
fed on a high-fat diet as assessed by flow cytometry. (P) Levels of IL-17A expression in spleen cells. Data are expressed as mean of 3 analyses ± SEM.
Differences between groups are shown. (Q) Representative analysis of CD4+IL-2+ T-cells in splenocytes from construct-immunized mice fed on a high-fat
diet as assessed by flow cytometer. (R) Levels of IL-2+ expressing CD4+ in spleen cells. Data are expressed as mean of 3 analyses ± SEM. Differences
between groups are shown.
doi:10.1371/journal.pone.0123393.g004
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Supernatants of splenocytes frommice immunized with these constructs individually showed
significantly increased secretion of IL-10 (Fig 4I) and TGF-β (Fig 4J), stimulated with 10 μg/mL
of ConA (P<0.05–0.001) when compared to those of controls. In addition, higher levels of either
IL-10 or TGF-β were produced by splenocytes of RPHC-immunized mice than those of AHHC-
immunized mice (P<0.05–0.01). In contrast, TNF-α (Fig 4K) and IFN-γ levels (Fig 4L) were sig-
nificantly decreased in the supernatants of splenocytes of mice immunized with these constructs
compared with the control when stimulated with 10 μg/mL of ConA. Notably, levels of TNF-α
and IFN-γ in RPHC-immunized mice were lower than those in AHHC-immunized mice
(P<0.05–0.01) when stimulated with 10 μg/mL of ConA, respectively. Interestingly, supernatants
of splenocytes frommice immunized were also shown to contain increased amount of protective
cytokine IL-10 and decreased amount of proinflammatory cytokine IFN-γ when stimulated with
either peptides or construct containing peptides but not in the case when stimulation was done
with KLH, a different protein (S3A–S3D Fig). In most cases, the changes in cytokine productions
in response to different stimulators were significant except for the cases when ApoB, C5aR and
Cpn peptides were used as stimulators for the production of IL-10 in GST-Den-immunized
mice, and PAR-1 peptide in RPHC-immunized mice.
The proportion of IL-4 (Th2-related), IL-17A (Th17 related) and IL-2 (Th1-related) ex-
pressing CD4+ spleen cells from mice immunized with these three constructs was significantly
lower (P<0.001 for IL-4+ and P0.001 for IL-17A+, respectively), showing 2.74 ± 0.11%
(AHHC), 2.85 ± 0.12% (RHHC), and 2.87 ± 0.02% (RPHC) for IL-4+ when compared to
8.44 ± 0.21% (control) (Fig 4M and 4N); 2.0 ± 0.1% (AHHC), 1.7 ± 0.1% (RHHC), and
0.9 ± 0.1% (RPHC) for IL-17A+ when compared to 4.1 ± 0.3% (control) (Fig 4O and 4P). In ad-
dition, smaller percentage of CD4+IL-17A+ expressing spleen cells was observed in RPHC-im-
munized mice compared to that in either AHHC- or RHHC-immunized mice (P0.006) (Fig
4O and 4P). Interestingly, higher percentage of CD4+IL-17A+ expressing spleen cells was ob-
served in RHHC-immunized mice compared to that in RPHC-immunized mice (P = 0.021)
(Fig 4P). Furthermore, significantly lower percentage of CD4+IL-2+ expressing spleen cells was
observed in three construct-immunized mice when compared to that in control (P<0.001; Fig
4Q and 4R). Additionally smaller percentage of CD4+IL-2+ expressing spleen cells was ob-
served in RPHC-immunized mice compared to that in either AHHC- or RHHC-immunized
mice (P = 0.019~0.007).
5. Evaluation of antigen-induced specific Treg cell function
To assess whether functional Treg cells were induced by immunization, we co-cultured anti-
gen-specific Treg cells (CD4+CD25+ T cells) with CD4+ effector T-cells (CD4+CD25- T cells).
Proliferation of effector T-cells from control mice immunized with GST-Den in response to
stimulation with GST-Den at 1μM did not show suppression in the presence of Treg cells from
GST-Den-immunized mice (Fig 5A and 5B). In contrast, proliferation of effector T cells from
sampling mice immunized with AHHC, RHHC and RPHC in response to stimulation with re-
lated antigen respectively was inhibited (Fig 5A and 5B), when CD4+CD25- effector T cells
were co-cultured with CD4+CD25+ Treg cells isolated from these mice. The differences were
significant when Treg cells were added to the effector cells at the ratios between 4:1~16:1
(P<0.05~<0.001) compared with that without the addition of Treg cells.
6. Evaluation of expression of smooth muscle alpha actins, VCAM1,
MMP9 and specific antigens ApoB and HSP60 in the lesions
To assess whether immunization with our constructs influences vascular SMC behavior and
vascular remodeling, we analysed the SMC content of lesions and expression of VCAM1 and
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MMP9 at lesion sites by IHC analyses. Anti-SMC stained area was significantly smaller in the
plaques of mice immunized with AHHC and RPHC, showing 5.2 ± 0.7% and 4.9 ± 0.8%, re-
spectively, but it was not reduced significantly in mice immunized with RHHC when compared
with that in controls immunized with GST-Den (Fig 6A and 6B). In addition, expression of
VCAM1 was significantly down-regulated, showing 4.5 ± 0.9%, 7.8 ± 0.9%, and 4.8 ± 0.9%, for
AHHC, RHHC and RPHC, respectively, compared with that in controls immunized with den-
droaspin (18.0 ± 2.3%) (Fig 6A and 6C). A significantly increased effect was found in RHHC-
immunized mice compared to that in AHHC- or RPHC-immunized mice (Fig 6A and 6C). A
similar trend was observed for MMP9 expression in mice immunized with all three constructs
7.9 ± 1.0%, 10.1 ± 1.0%, and 7.6 ± 1.0% stained areas were shown in AHHC-, RHHC- and
RPHC-immunized mice, respectively, and 18.1 ± 2.5% in control mice immunized with
GST-Den (Fig 6D and 6E), except for that there is no significant difference obtained in this re-
spect between either AHHC- or RPHC-immunized mice and RHHC-immunized mice (Fig 6D
and 6E). Interestingly, the injection of recombinant construct containing human ApoB and
HSP60 peptides did not affect the expression of their counterparts (ApoB and HSP60) as little
difference of mouse ApoB (S4A and S4B Fig) and mouse HSP60 protein (S4C and S4D Fig) an-
tigens was detected at the lesion sites between sampling and control mice.
7. Evaluation of monocyte differentiation into macrophages in PBMC
from C57BL/6 background naive mice in response to treatment with
recombinant constructs; effect of construct-specific immune sera on the
differentiation
In vitro, monocytes can differentiate into macrophage (or subsets) upon stimulation with mac-
rophage-colony stimulating factor (M-CSF) [21] or atherogenic antigens [17]. To assess wheth-
er AHHC converted into RHHC with a single domain substitution could maintain the same
effect on stimulation of monocyte (from naive mice C57BL/6 with same background), PBMCs
were stimulated with either RHHC or AHHC. After 3 days, the expression of cell surface
Fig 5. Investigation of antigen-specific regulatory function in antigen-immunizedmice. Inhibition of CD4+CD25- effector T cell proliferation by
CD4+CD25+ regulatory T-cells isolated from the spleen of control (GST-Den–immunized) and construct-immunized mice when AHHC, RHHC and RPHC
were used as antigens. (A) Quantitative analyses of proliferation of CD4+CD25- effector T cells in the presence of Treg cell by flow cytometry is shown. (B)
Proliferation of effector cells isolated from immunized mice alone is indicated in the leftmost bar of each group. Addition of Treg cells to T effector cells at
different ratios was also shown. Data are given as mean of 3 analyses ± SEM.
doi:10.1371/journal.pone.0123393.g005
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marker CD206 (mannose receptor, a macrophage marker) was assessed. Both RHHC- and
AHHC-induced monocyte differentiation into macrophages (based on the cell number
changes) when compared with non-stimulated cells (Fig 7A and 7B). In addition, PBMC differ-
entiation induced by these two constructs was abolished by pre-incubation of the cells with an-
tiserum from mice immunized with these two antigens. Interestingly, the inhibition can be
achieved by pre-incubation of the cells with antiserum from each other (Fig 7A–7D). Observa-
tion of differentiations with individual epitope or domain as a stimulator showed different
ratio of differentiation (Fig 7E and 7F).
8. Evaluation of the contents of Toll-like receptor 4(TLR4) and myeloid
differentiation factor 88 (MyD88) which are involved in the TLR4 signal
pathway related to atherosclerosis at the lesion sites
We examined the impact of the treatment with these recombinant constructs on TLR4 and
MyD88 contents in lesions. The reduction of atherosclerosis in mice treated with these con-
structs was associated with a decrease in both TLR4 and MyD88 contents. Anti-TLR4 stained
area was significantly smaller in the plaques of mice immunized with AHHC, RHHC and
Fig 6. Evaluation of expression of smoothmuscle alpha actins, vascular cell adhesionmolecule (VCAM)1 andmatrix metalloproteinase 9 (MMP9)
in lesion site. (A) Photomicrographs showing IHC staining for smooth muscle alpha actin (red), vascular cell adhesion molecule VCAM1(green) (scale bar:
100 μm and 12.5μm for magnified ones). (B) anti-SMC stained area. (C) Scatter plot showing means of anti-VCAM-1 stained area (N = 6). (D)
Photomicrographs showing IHC staining for MMP9 (green) (scale bar: 100 μm and 12.5μm for magnified ones). (E) Scatter plot showing means of anti-MMP9
stained area (N = 6).
doi:10.1371/journal.pone.0123393.g006
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RPHC, showing 4.6 ± 1.0%, 3.4 ± 0.5% and 4.2 ± 0.6%, respectively, compared with that in con-
trols immunized with dendroaspin (8.1 ± 1.1%) (Fig 8A and 8B). Similarly, anti-MyD88
stained area was significantly smaller in the lesions of mice immunized with these three con-
structs, showing 9.7 ± 1.2%, 9.6 ± 1.6% and 10.2 ± 1.9%, respectively, compared with that in
controls (18.6 ± 2.4%) (Fig 8C and 8D). Additionally, overlapping anti-CD11c and anti-TLR4
stained area showed significantly smaller in the lesions of mice immunized with all three con-
structs, showing 3.4 ± 0.6%, 2.9 ± 0.7% and 2.7 ± 0.8%, respectively, compared with that in con-
trols (6.6 ± 0.8%) (S5A and S5B Fig).
Fig 7. Evaluation of monocyte differentiation into macrophages. (A and B) PBMCs differentiation stimulated by recombinant constructs (1 μg/ml) as
assessed by analyses of CD206 expression by flow cytometry and inhibition of differentiation in the presence of respective construct-induced antibodies. (C
and D) Inhibition of differentiation by respective and other construct induced antibodies. (E and F) Individual peptide as a stimulator (1 μg/ml) of monocyte
differentiation as analysed by CD206 expression. Data are expressed as average values of 3 analyses.
doi:10.1371/journal.pone.0123393.g007
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Discussion
We have reported the atherosclerotic lesion reducing effect of immunization with a recombi-
nant construct AHHC containing epitopes derived from ApoB, hHSP60 and Cpn [16] and that
the C5aR N-terminal peptide has a similar effect on lesion reduction [17]. In this study, we
have investigated whether the lesion reducing effect can be increased by using a construct ei-
ther with a single peptide substitution in AHHC! RHHC or with double substitutions in
AHHC! RPHC in B6;129S-Ldlrtm1HerApobtm2Sgy/Jmice.
Fig 8. Evaluation of the content of TLR4 and MyD88 contents at the lesion sites. (A) Photomicrographs showing IHC staining for TLR4 (red) (scale bar:
100 μm and 12.5μm for magnified ones). (B) Scatter plot showing means of anti-TLR4-stained area (N = 6). (C) Photomicrographs showing IHC staining for
MyD88 (red) (scale bar: 100 μm and 12.5μm for magnified ones). (D) Scatter plot showing means of anti-MyD88-stained area (N = 6).
doi:10.1371/journal.pone.0123393.g008
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PAR-1 peptide was selected for antigen component as immunization with this peptide re-
sulted in reduced lesion formation in a pilot experiment (Xia et al unpublished data).
B6;129S-Ldlrtm1HerApobtm2Sgy/Jmouse strain was used because these mice show a high degree
of atherosclerosis after being fed a high-fat diet [22].
Our results suggest that immunization with all three recombinant constructs induces an an-
tigen-specific antibody response except for PAR-1 and hHSP60 peptide-1. The induced im-
mune response is associated with an anti-atherogenic effect, detected as a significant reduction
in the size of the atheromatous lesion area both in aorta sinus and descending aortas with a
rate in the following order: RPHC RHHC>AHHC.
Immunization with RHHC in 10-week, high-fat diet (HFD)-based B6;129S-Ldlrtm1HerA-
pobtm2Sgy/Jmouse model led to a high antibody response against C5aR peptide. Low level of an-
tibody response against hHSP60153-163 and increased antibody responses either against
hHSP60303-312 or Cpn peptide in RHHC were observed. In RPHC-immunized mice, low IgG
responses against PAR-1 peptide and hHSP60 peptide-1, but high antibody responses against
C5aR peptide as well as Cpn peptide were achieved. The peptides (e.g. hHSP60153-163 or PAR-1
peptide) in either RHHC or RPHC failed to induce IgG response which may be due to steric
hindrance or these peptides were not exposed on the surface of the molecule. However, this
may not constitute an impact on lesion reduction as according to our previous results AH
(containing both ApoB and hHSP60153-163 peptides) construct-immunized mice showed
higher lesion reduction than either ApoB peptide- or hHSP60153-163 peptide-immunized mice
[16]. The results from our study also show that immunization induced an IgG1 isotype specific
to most antigen peptides when an individual peptide was used as an ELISA antigen. The results
of total IgG showed immune response persisting at week 12 (detectable at 100-fold dilutions)
in spite of slightly lower OD values at week12 than that at week 2. However, these peptides
could induce only a weak peptide-specific IgG2c-isotype response based on the OD values, sug-
gesting that vaccination with these peptides acts predominantly through the Th2 pathway.
Cellular infiltration into atherosclerotic lesions results in increased levels of macrophages,
activated CD4+ T cells, and dendritic cells (markers of early lesion formation) [23]. We ob-
served that due to immunization with all three constructs, lower numbers of macrophages, and
CD11c+ cells, and higher number of Treg cells was detectable in the atherosclerotic lesions
than in those of control mice and also these numbers showed similar trend when RHHC-im-
munized mice were compared with AHHC-immunized mice and when RPHC-immunized
mice were compared with RHHC-immunized mice.
In agreement with the results of the present study, Cybulsky et al reported that cells bearing
markers of dendritic cells (DCs), including CD11c, take up residence just beneath the endothe-
lium in the lesser curvature of aorta in mice [24]. Moreover, the results of our study show that
CD68+CD11c+ cells are the main macrophage subset in lesions, but their functions, and wheth-
er their function is affected by the constructs, need to be further explored [20]. Vaccination
using mature DCs pulsed with oxidized low-density lipoprotein (oxLDL), or oxLDL-specific T
cells with a lowered Th1 response increased the levels of oxLDL-specific antibodies and re-
duced the lesion size [25]. Therefore, it will be interesting in future studies to determine wheth-
er vaccination using mature DCs pulsed with these recombinant constructs could induce
specific T cells and could reduce lesion size.
TNF-α and IFN-γ are crucially involved in the progression of atherosclerosis [26–28]. On
the basis of the cytokine profiles from either plasma or supernatant of splenocytes in immu-
nized mice, TNF-α and IFN-γ secretion may well be linked to the ability of the immune ani-
mals to release these cytokines from preprimed cells, leading to a decrease in the need to
synthesize significant amounts of new TNF-α and IFN-γ. Our results show that immunization
with RPHC, RHHC and AHHC promoted a major shift away from proinflammatory cytokines
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(TNF-α and IFN-γ) towards anti-inflammatory cytokines (IL-10 and TGF-β), which is evident
not only in the plaque but also systemically at remote sites (splenocytes). These results strongly
suggest that an anti-inflammatory response is responsible for the observed reduction in plaque
size, they do not discriminate the reductions attributed to either of the anti-inflammatory cyto-
kines, as both IL-10 and TGF-β, the two major cytokine products of Treg, have been implicated
in playing a role in atherosclerosis [29,30]. Our results also showed these antigens have anti-
genic effect which elicited increased atheroprotective cytokine IL-10 (Th2 cytokine) and de-
creased proinflammatory cytokine IFN-γ (Th1 cytokine) in spleen cell of antigen-immunized
mice. Further evidence was obtained from CD4+ T cell expressing cytokines, IL-4, IL-17A and
IL-2. IL-4, a major cytokine directing differentiation of Th0 cells to Th2 cells [31], is the signa-
ture cytokine of Th2 lymphocytes and expressed by T cells in atheroma of severely hyper-
cholesterolemic ApoE−/−mice [32]. IL-4 has been shown to influence cell adhesion by causing
an increase in expression of VCAM1 by endothelial [33] and of vascular smooth muscle cells
[34], whereas IL-17A, a predominant IL-17 family member, have recently been detected within
human and mouse atherosclerotic vessels [35]. Elevated plasma IL-17 was found in patients
with coronary artery disease (CAD) in comparison with healthy controls [36]. In addition, ex-
pression of IL-17A in human atherosclerotic lesions is associated with increased inflammation
and plaque vulnerability [37]. Furthermore, the presence of both IL-17A and IFN-γ in clinical
specimens of coronary atherosclerosis and the presence of IL-17A/IFN-γ double producer T
cells within coronary plaques were reported [36]. In agreement with the data on the IL-4 and
IL-17A, our results showed that the number of CD4+ T cell expressing IL4 and IL-17A in mice
immunized with our three constructs was significantly reduced. In addition, the lowest per-
centage of the IL-17A expressing CD4+ T cell population was achieved by immunization with
RPHC construct as antigen, whereas lower percentage of CD4+ T cell expressing IL-17A was
also observed in RHHC-immunized mice than in AHHC-immunized mice. Furthermore, our
results showed that the number of CD4+ T cell expressing IL-2 (Th1 cell-related) in mice im-
munized with our three constructs was significantly decreased. IL-2, a pro-inflammatory T cell
cytokine, is a cytokine mainly produced by activated T cells [38]. Our results suggest that IL-2
may promote atherosclerosis.
Next we investigated whether Tregs played a role in reducing atherosclerotic lesion forma-
tion by immunization with RPHC and RHHC as well, in case of AHHC it is, at least in part,
due to increased Treg cell concentration in immunized mice, either locally (in the lesions) or in
remote organs (splenocytes): we observed that concentrations of CD4+ Treg cells were signifi-
cantly higher in mice immunized with recombinant constructs than of those either locally (in
lesion site of aorta) or in remote organs (splenocytes) in control mice immunized with
GST-Dendroaspin. In addition, Foxp3+ population in RPHC-immunized mice was significant-
ly higher than that in AHHC-immunized mice, suggesting functional and structural differences
between these two antigens that may contribute to the increased Foxp3+ population. We also
demonstrated that the atheroprotective effect paralleled an induction of functional Treg cells
that suppressed antigen-specific proliferation of effector T cells, thus suggesting that Tregs
have an active role in the control of the atherosclerotic process. Treg cells are characterized by
the expression of Foxp3, which has a crucial role in their suppression function [35].
Clinical data showed that Th17/Treg functional imbalance exists in patients with acute cor-
onary syndrome (ACS), a significant decrease in Treg number, Treg-related cytokines (IL-10
and TGF-β1), and Foxp3 levels, suggesting a potential role for Th17/Treg imbalance in plaque
destabilization and the onset of ACS [39]. It appears that modulation of atherosclerosis-related
autoimmunity by antigen-specific activation of Tregs represents a novel approach for the treat-
ment of atherosclerosis.
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It is known that expression of smooth muscle alpha actin is altered in pathological condi-
tions of atherosclerosis and the existence of alpha-smooth muscle actin-positive endothelial
cells in adult aortic endothelium is associated with progression of atherosclerosis [40]. In addi-
tion, the atherosclerotic vessel wall contains a range of adhesion molecules [41] and inflamma-
tory cytokines [42], which may permit attachment and subsequent differentiation of marrow
derived cells into smooth muscle cells within plaque [43]. Furthermore, several matrix metallo-
proteinases have been reported to play roles in atherosclerosis such as MMP-9 [44]. The lesion
development is initiated by infiltrating macrophages that mainly produce MMP-9 as well as
MMP2 [45]. Our results showed that mice immunized with all three antigens have the lower
expression of alpha-SMCs, VCAM1 and MMP9 when compared to the control animals.
Monocytes play important roles in the initiation, progression, and complications of athero-
sclerosis. Their differentiation to macrophages can be modulated by factors present within the
microenvironment of the artery wall, such as oxidized lipids, TLR ligands, cytokines, and che-
mokines [21]. It should be noted that macrophages can be differentiated into various macro-
phage subsets with different cell surface markers; further discrimination of macrophage subsets
is planned in our future studies. Our in vitro study showed that these constructs can be used as
stimulators of monocyte to macrophage differentiation. The antibodies against these constructs
can be served as inhibitors in this respect, suggesting antibody elicited by immunization may
have similar property to reduce monocyte differentiation in vivo, as ApoB, HSP60, C5aR (from
which the peptide epitope derived) were detected in the atherosclerotic lesion sites in our pres-
ent and previous studies [17] which may serve as endogenous ligands.
Additionally, macrophages serve as the major immune cells in the lesion and they express
pattern-recognition receptors, including Toll-like receptors (TLRs) that connect the innate and
adaptive immune response during atherosclerosis. The mechanisms involved in signaling path-
ways, which link TLR4 (also serving as a Th1 marker) to the proinflammatory transcription
factor nuclear factor κB (NF-κB), occur through MyD88, a general adaptor protein down-
stream of TLRs (except for TLR3) and the receptors of the IL-1R family [46,47]. MyD88 signal-
ing causes defects in pro-inflammatory cytokine production and innate immune cell
activation, permitting the development of a high pathogen burden [48]. In agreement with the
report by Subramanian et al. [49], our results show that both TLR4 and MyD88 contents as
well as common occupied lesion area by TLR4 and CD11c were significantly reduced in mice
immunized with recombinant constructs, indicating that TLR4/MyD88 pathway was down-
regulated in these antigen-immunized mice, however, the pathways that link TLRs to pro-ath-
erogenic effectors in immune cells remain under investigation.
Collectively, the results showed that all three constructs are potent antigenic constructs and
these constructs can be modulated towards more effective inhibition of atherosclerotic plaque
formation via reducing proinflammatory cells, cytokines and increasing anti-inflammatory
cells, cytokines and the proportion of Tregs as statistically shown in S1 Table. The effect of
change of immune parameters in the plaques, cell-to-cell interaction (Treg cell and T effector
cell; Treg cell and monocyte/macrophage) and immune cross-reactivity between paired epi-
topes (A, R and P) may contribute to favorable plaque phenotype and increased lesion reduc-
tion as shown in RHHC and RPHC. The immune response induced against the involved
peptide antigens reduces the plaques in mice. It is acceptable that ApoB and HSPs are self
antigens which might induce immune response causing damage to the vessel wall and cause
inflammation. In this case, these antigens induced regulatory T cells which can be atheropro-
tective. In the case of PAR-1 and C5aR, their antibodies may be able to prevent activations
of atherogenic pathways. Further study on knockout mice with these receptors are needed.
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The study highlights application of antigen-specific immunomodulation in which Treg-me-
diated suppression of atherosclerosis requires TLR4/MyD88 signaling and this immunomodu-
lation permits selective inactivation of auto-reactive T cells without interfering with normal
immune function [46] as our results have shown the similar profiles of autoantigen ApoB and
HSP60 at the lesion sites in both control and sampling animals. Indeed sequence alignment by
using“SIM” software shows 69.7% and 97.6% identity for ApoB and HSP60, respectively be-
tween mouse and human (data not shown). Atheroprotection by immunization with these con-
struct is likely to be mediated by both a humoral and a cell-mediated regulatory response to the
antigen. Our findings have suggested that developing a protein-based vaccine using a den-
droaspin scaffold with rearrangement of different peptide sequence(s) may offer attractive op-
portunities for the development of multivalent vaccines against atherosclerosis.
Supporting Information
S1 Fig. Schematic representations of dendroaspin structure and constructs. A. Schematic
representation of the backbone of dendroaspin structure [1]. B. Schematic representation of
alignment of constructs in dendroaspin scaffold.
(TIF)
S2 Fig. Detection and quantitation of the lesion areas in the aorta of B6;129S-Ldlrtm1HerA-
pobtm2Sgy/Jmice fed on a high-fat diet at week 9 after immunization with constructs versus
controls (GST-Den), GST and alum. A. Photomicrograph of lesions observed in atheroscle-
rotic aortas as analyzed with elastin/van Gieson staining (N = 6–8 mice). B. Scatter plot show-
ing mean of lesion area in the aortic sinus of mice (N = 6-8mice).
(TIF)
S3 Fig. Assessment of ApoB and HSP60 in the lesions of B6;129S-Ldlrtm1HerApobtm2Sgy/J
mice fed a high-fat diet after immunization with constructs AHHC, RHHC, and RPHC. A.
Representative photomicrographs showing immunohistochemical staining of the aortic root
showed anti-ApoB antibody stained areas (red) in the lesion. B.Quantitative analysis of ApoB
content in lesions. C. Representative photomicrographs showing immunohistochemical stain-
ing of the aortic root showed anti-HSP60 antibody stained areas (red) in the lesion. D.Quanti-
tative analysis of HSP60 content in lesions. Scale bar: 150 μm (unenlarged) and 25 μm
(enlarged). N = 6 mice. NS: not significant.
(TIF)
S4 Fig. Measurement of cytokines in the supernatant of spleen from immunized mice stim-
ulated by either GST-Den or constructs. A. IFN-γ from GST-Den-immunized mice. B. IFN-γ
from construct-immunized mice). C. IL-10 from GST-Den-immunized mice.D. IL-10 from
construct-immunized mice). Splenocytes were cultured in RPMI 1640 with 10% fetal calf
serum and induced with1 μg/ml antigen (GST-Den, GST-AHHC, GST-RHHC, GST-RPHC,
ApoB100 peptide, C5aR peptide, PAR-1 peptide, respectively) for 48 hour. Then IL-10 and
IFN-γ in supernatant of cultured cell were measured with DuoSet mouse IL-10 kit and mouse
IFN-γQuantikine immunoassay kit (R&D system, Minneapolis) according to manufactory’s
protocol.
(TIF)
S5 Fig. Detection and quantitation of TLR4 overlapped with CD11c in lesion area. A. Rep-
resentative photomicrographs showing immunohistochemical staining of the aortic root
showed anti-TLR4 antibody stained areas (red) overlapped with anti-CD11c antibody stained
area (green) in the lesion (overlapped area is in yellow). B.Measurement of combined (TLR4
Antigenic Effect on Lesion Reduction in KOMice
PLOS ONE | DOI:10.1371/journal.pone.0123393 April 1, 2015 18 / 21
and CD11c) area occupied in lesion (%). Scale bar: 141 μm (unenlarged) and 26 μm (enlarged).
(TIF)
S1 Table. Statistical analysis of the effects of immunization with the constructs.
(DOCX)
S1 Text. Materials and methods.
(DOCX)
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